-
Gleevec Associated With Long-Term Effectiveness in Treating GIST
17 Sep 2025 19:48 GMT
… Cancer Institute on its website, is a type of drug … treat certain types of leukemia and other blood … Oncology.
“Gleevec,” National Cancer Institute; https://www.cancer.gov… dictionaries/cancer-terms/def/gleevec
“About Gastrointestinal …
-
Patent Office Revokes Patent for Novartis’ Cardiac Drug
17 Sep 2025 13:24 GMT
… the patent on Novartis’ blockbuster cardiac drug Vymada on grounds … courts restrained them following Novartis’ legal action. With the … Notably, Novartis had earlier lost its patent on cancer drug Glivec in … efficacy.”
High Stakes for Novartis
Vymada is a major …
-
Federal Funding Drives Breakthroughs in Cancer Research, AACR Report Shows
17 Sep 2025 06:54 GMT
… imatinib’s (Gleevec) 2001 approval for chronic myeloid leukemia (CML), revolutionized … -onset cancer, cancer disparities, CAR T-cell therapy, antibody-drug conjugates
Tags … : AACR Cancer Progress Report 2023advancements …
-
The 15th AACR cancer progress report highlights scientific advances
17 Sep 2025 06:33 GMT
… , the National Cancer Institute (NCI), the U.S. Food and Drug Administration … FDA, imatinib (Gleevec), was approved to treat chronic myeloid leukemia (CML) in … nearly half of all new cancer drugs, leading the world in the …
-
Why India revoked patent of Novartis’ cardiac drug and why it matters
16 Sep 2025 18:36 GMT
… has revoked the patent on Novartis’ cardiac drug Entresto, sold as Vymada … major domestic drugmakers, opposed the patent on Novartis’ heart-failure drug Vymada.
The … 2013, Novartis had lost the patent on its blockbuster cancer drug Glivec under the …
-
In major move, patent of Novartis' blockbuster cardiac drug revoked by India
16 Sep 2025 07:35 GMT
… has revoked the patent on Novartis’ blockbuster therapy Vymada, citing … heart failure. For Novartis, the drug is a major revenue … access to affordable medicines.
Novartis’ patent, filed in 2007 … 2013 when Novartis lost its claim on the cancer drug Glivec.
The …
-
India revokes patent of Novartis' cardiac drug
16 Sep 2025 06:41 GMT
… patent on Novartis' cardiac blockbuster drug Vymada on … which Novartis also lost the patent on its blockbuster cancer drug Glivec …
A questionnaire mailed to Novartis failed to elicit a … same drug expired in 2023.
"The patentee (Novartis) abstained …
-
Israel Cancer Research Fund Surpasses $100 Million in Total Funding as New Grants Are Awarded
11 Sep 2025 04:22 GMT
… non-governmental funder of cancer research in Israel, today … approved targeted therapies (Doxil®, Gleevec®, and Velcade®). Two Nobel … more information about Israel Cancer Research Fund, visit www … 302552631.html
SOURCE Israel Cancer Research Fund
COPYRIGHT …
-
Meta-Analysis Highlights Efficacy, Safety Benefits With Asciminib in Chronic Myeloid Leukemia
04 Sep 2025 21:29 GMT
… patients with chronic myeloid leukemia (CML) in chronic phase … TKI, such as imatinib (Gleevec), bosutinib (Bosulif), ponatinib (Iclusig … -342.
Scemblix. Prescribing information. Novartis; 2024. Accessed September 4, … en/sites/novartis_us/files…
-
Cancer Focus Fund Appoints Distinguished Industry Experts David R. Epstein and Michael Margolis as Advisors to Its Investment Committee
04 Sep 2025 11:00 GMT
… years of global biopharmaceutical drug development, dealmaking, commercialization … new molecular entities, including Glivec, Tasigna, Gilenya, Cosentyx, … and Licensing Group at Novartis Pharmaceuticals and as … Partner of Cancer Focus Fund. “Cancer Focus Fund’ …
About
© 1995-2025